Cargando…
Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
Autores principales: | Einarsdottir, Berglind O., Karlsson, Joakim, Söderberg, Elin M. V., Lindberg, Mattias F., Funck-Brentano, Elisa, Jespersen, Henrik, Brynjolfsson, Siggeir F., Bagge, Roger Olofsson, Carstam, Louise, Scobie, Martin, Koolmeister, Tobias, Wallner, Olof, Stierner, Ulrika, Berglund, Ulrika Warpman, Ny, Lars, Nilsson, Lisa M., Larsson, Erik, Helleday, Thomas, Nilsson, Jonas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005267/ https://www.ncbi.nlm.nih.gov/pubmed/32029719 http://dx.doi.org/10.1038/s41419-020-2301-y |
Ejemplares similares
-
A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2018) -
Karonudib is a promising anticancer therapy in hepatocellular carcinoma
por: Hua, Xiangwei, et al.
Publicado: (2019) -
Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts
por: Bhadury, Joydeep, et al.
Publicado: (2016) -
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017) -
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)